{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 11:', 'List of Abbreviations and Definitions of Terms (Continued)', 'OLE', 'Open-Label Extension', 'oMG', 'ocular myasthenia gravis', 'PD', 'pharmacodynamic(s)', 'PE', 'plasma exchange', 'PIS', 'post-intervention status', 'PP', 'plasmapheresis', 'PK', 'pharmacokinetic(s)', 'PNH', 'paroxysmal nocturnal hemoglobinuria', 'PPS', 'Per protocol set', 'Q2W', 'every 2 weeks', 'Q8W', 'every 8 weeks', 'QMG', 'Quantitative Myasthenia Gravis score for disease severity', 'QoL', 'quality of life', 'QT', 'interval between the start of the Q wave and the end of the T wave in', 'an ECG', 'QTc', 'corrected QT interval', 'SAE', 'serious adverse event', 'SAP', 'statistical analysis plan', 'SC', 'subcutaneous', 'SO2', 'oxygen saturation', 'SoA', 'Schedule of Activities', 'SOC', 'system organ class', 'SUSAR', 'suspected unexpected serious adverse reaction', 'TAC', 'tacrolimus', 'TEAE', 'treatment-emergent adverse event', 'TESAE', 'treatment-emergent serious adverse event', 'Page 103 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.18.', 'Appendix 18: Protocol Amendment History', 'Amendment 1 (11 Dec 2018)', 'This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of', 'Directive 2001/20/EC of the European Parliament and the Council of the European Union.', 'Overall Rationale for the Amendment', 'To change duration of safety follow-up after last dose; add additional details on assessments,', 'align pregnancy and clinical laboratory testing frequency with infusions; change supplemental', 'dosing recommendations and sample collection when rescue therapy is provided; and update', 'adverse event and pregnancy/contraception language.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 1.1: Synopsis; Section 4.1:', 'Patients will be followed for safety for', 'A 24-week follow-up in', 'Overall Design; Section 7.1:', '8 weeks after last dose of study drug.', 'patients is not feasible as', 'Discontinuation of Study', 'safety data would likely be', 'Intervention; Section 8.3.1: Time', 'confounded by new', 'Period and Frequency for Collecting', 'treatments.', 'Adverse Event and SAE Information', 'To align with duration of', 'safety follow-up for other', 'ravulizumab programs.', 'Section 1.3: Schedule of Activities', 'Changed terminology of targeted', 'To align with terminology', 'physical examination to abbreviated', 'for physical examination.', 'physical examination throughout', 'protocol.', 'To ensure appropriate C-', 'Clarification that C-SSRS', 'SSRS versions are', 'Baseline/Screening Version assessment', 'administered.', 'will occur on Day 1 and C-SSRS Since', 'Last Visit Version assessment will', 'occur on subsequent indicated visits.', 'Added reference to section detailing', 'To precisely specify', 'assigned evaluator for assessment', 'appropriate evaluator for', 'instruments.', 'each assessment instrument.', 'Frequency of Clinical Lab Test and', 'To align with infusion visits', 'Pregnancy Test assessments reduced', 'and reduce burden on', 'and aligned with infusion visits.', 'patients.', 'Clarified PK/PD and ADA sample', 'To ensure PK/PD and ADA', 'collection should occur in the event of', 'analyses are performed', 'Clinical Deterioration.', 'consistently across events if', 'Clinical Deterioration occurs.', 'Section 4.2.2: Unscheduled Visits', 'Specified that efforts will be made to', 'To ensure data is associated', 'map unscheduled visit data with the', 'with the appropriate visit.', 'appropriate visit in the eCRF.', 'Section 4.2.3: Properly Trained', 'Removed EQ-5D-5L and MG-QOL15r', 'To clarify as these', 'Clinical Evaluator', 'from section as these instruments are', 'assessments are completed', 'completed by patients.', 'by patients.', 'Section 4.2.4: Responsibilities for', 'Removed EQ-5D-5L and MG-QOL15r', 'To clarify as assessments are', 'Myasthenia Gravis Assessments', 'from Myasthenia Gravis Assessments', 'completed by the patient.', 'and Responsibilities table.', 'Page 104 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 6.1: Study Drugs', 'Updated Table 6 to indicate volumes', 'To ensure proper preparation', 'Administered', 'needed for ravulizumab, placebo, and', 'of placebo and ravulizumab', 'diluent.', 'doses.', 'Section 6.2.4: Accountability', 'Updated details for study drug', 'To ensure proper', 'accountability to reflect use of', 'accountability of study drug', 'interactive response technology (IRT)', 'while using IRT.', 'and study monitors.', 'Section 6.2.5: Handling and Disposal', 'Provided details for study drug handling', 'To provide additional details', 'and disposal.', 'on proper handling and', 'disposal of study drug.', 'Section 6.5.1.4: Plasma', 'Updated timing and dosing levels for', 'To ensure proper and', 'Exchange/Plasmapheresis/Intravenous', 'supplemental study drug administration', 'consistent dosing of', 'Immunoglobulin', 'when PE/PP or IVIg rescue therapy is', 'supplemental study drug', 'provided.', 'following PE/PP or IVIg.', 'Section 8.1.1: Hospitalization', 'Updated definition of hospitalization.', 'To ensure admission to', 'facility overnight is collected', 'as hospitalization.', 'Section 8.1.2: Clinical Deterioration', 'Section 10.2 (Appendix 2) referenced in', 'To align with Section 10.2', 'clinical laboratory tests.', '(Appendix 2): Clinical', 'laboratory tests.', 'MG Crisis or Clinical Deterioration', 'Visit changed to Clinical Deterioration', 'To provide consistency with', 'Visit.', 'Clinical Deterioration', 'criteria.', 'Section 8.2.5.1: Columbia-Suicidal', 'Updated to detail the C-SSRS will be', 'To align with other sections', 'Severity Rating Scale', 'administered by the Investigator or a', 'of the protocol indicating the', 'properly trained designee.', 'Investigator or a properly', 'trained designee will', 'administer the assessment.', 'Section 8.3.1: Time Period and', 'Updated language on submission of', 'To align with current', 'Frequency for Collecting Adverse', 'SAE data.', 'practices.', 'Event and SAE Information', 'Section 8.3.4: Regulatory Reporting', 'Added language on reporting of', 'To align with regulatory', 'Requirements for Serious Adverse', 'SUSARs.', 'feedback on ravulizumab', 'Events', 'program.', 'Section 8.3.5: Pregnancy; Section 1.3:', 'Updated to indicate that serum', 'To align with Table 1 and', 'Schedule of Activities', 'pregnancy testing will occur at', 'Table 2 of Schedule of', 'Screening and at the End of Study.', 'Activities.', 'Section 10.2 (Appendix 2): Clinical', 'Added serum follicle stimulating', 'To fix inconsistencies', 'Laboratory Tests', 'hormone and urine creatinine testing.', 'between protocol sections', 'Removed D-dimer and free hemoglobin', 'and remove D-dimer and free', 'testing.', 'hemoglobin assessment.', 'Section 10.3.4 (Appendix 3):', 'Updated to clarify that the expectedness', 'To ensure Reference Safety', 'Recording and Follow-Up of Adverse', 'and reporting criteria of an SAE will be', 'Document is used when', 'Event and/or Serious Adverse Event', 'based on the Reference Safety', 'recording an AE.', 'Document.', 'Section 10.4.1 (Appendix 4):', 'Updated to indicate that male patients', 'To align with current', 'Contraception Guidance', 'must not donate sperm and female', 'Alexion language.', 'patients must not donate ova while on', 'treatment and for at least 8 months after', 'the last dose of study drug.', 'Section 10.4.3 (Appendix 4):', 'Updated language on collection and', 'To align with current', 'Collection and Reporting of', 'reporting of pregnancy information.', 'Alexion language.', 'Pregnancy Information', 'Page 105 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}